Yun Michael Shim, MD

Highlights

1
Thorax · 2020
YMYun Michael Shim
PMID: 33139449PMCID: PMC7815893DOISenior author32 citations
2
International journal of chronic obstructive pulmonary disease · 2020
YMYun Michael Shim
PMID: 32021142PMCID: PMC6955613DOISenior author7 citations
3
American journal of respiratory and critical care medicine · 2026
YMYun Michael Shim
PMID: 41135035DOIFirst author

31

4 grants

Sub-PI
Developing Hyperpolarized Gas MRI signatures to detect and manage acute cellular rejection
National Heart, Lung, and Blood Institute · 2026–2029 · via University of Virginia
R01HL173369-03
PI
Dissolved Phase Hyperpolarized Xenon-129 MRI: a novel biomarker to quantify pulmonary pathology in young healthy e-cigarette users
NIDA · 2024–2029 · via NIH RePORTER
R01DA059660-03
PI
Multi-omic Characterization of COPD in Females
NHLBI · 2024–2028 · via NIH RePORTER
R01HL173869-03
PI
Sexual dimorphism in susceptibility to emphysematous tissue injury
NHLBI · 2023–2027 · via NIH RePORTER
R01HL167202-04

Completed grants (5)

PI
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics
NHLBI · 2017–2023 · via NIH RePORTER
R01HL132177-05
PI
Discovery of New Anti-Inflammatory Agents to Treat COPD
NHLBI · 2016–2022 · via NIH RePORTER
R01HL132287-04
PI
Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema
NHLBI · 2013–2015 · via NIH RePORTER
R41HL115965-01A1
PI
Biology of Leukotrienes in the Pathogenesis of Emphysema
NHLBI · 2008–2014 · via NIH RePORTER
K08HL091127-05
MPI
BIOLOGY OF CYTOKINES AND 5-LO IN THE PATHOGENESIS OF EMPHYSEMA
NCRR · 2009–2010 · via NIH RePORTER
M01RR000847-36

Alpha One Therapeutics INC

Alpha One Therapeutics INC

Alpha One Therapeutics INC